BeNeLuxBelgiumNetherlandsLuxembourg

Fluorescent tumours in the clinic

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted dyes in patients. Now for the first time, a Dutch-German team of researchers has found a way to convince regulatory authorities that their fluorochromes are safe and can be tested on human subjects. In November, the team got the go-ahead for a Phase I study in breast cancer patients with the fluorochrome IR dye 800 CW (LI-COR Bioscience) coupled to the antibody drug Avastin (Roche).
“Our advantage is that we already have a lot of clinical data about the safety and biodistribution of the cancer therapeutic Avastin, which binds to VEGF produced by cancer cells,” said Werner Scheuer from Pharma Research & Early Development at Roche (Penzberg), who developed the anti­body-flurochrome conjugates in cooperation with Vasilis Ntziachristos (TU Munich) and Go van Dam (Medical College Groningen). In the November issue of the Journal of Nuclear Medicine (52(11): 1778-1785), the authors provided evidence that their cancer imaging agent behaves in animals as Avastin does in humans. For proving safety in humans, they will use microdoses of the dye – 100 times lower than the lowest dose in which the cancer drug shows an effect. “We want to statistically prove that breast cancer patients benefit from image-guided surgery with targeted fluorochromes,” explains Ntziachristos. He has developed a camera system that can identify the tumour margins with seven times better resolution than a surgeon can with the naked eye. A pipeline of antibody-fluorochrome conjugates is already being tested in animals.

BeNeLuxBelgiumNetherlandsLuxembourg

14.08.2008

Gent – Belgian Innogenetics NV is the object of a bidding war. After chemical company Solvay tendered its offer to acquire 93% of the diagnostics specialist in April, San-Diego-based Gen-Probe also entered the arena, offering to...

BeNeLuxBelgiumNetherlandsLuxembourg

14.08.2008

Belgian Ablynx N.V. (Ghent) has started a Phase Ib safety and dose-finding study of ALX-0081, an antithrombotic antibody fragment that targets von Willebrand factor (vWF).

BeNeLuxBelgiumNetherlandsLuxembourg

14.08.2008

Amsterdam Molecular Therapeutics finished enrolment in its Phase III trial in mid-June in its AAAV-based gene therapy AMT-011 (Glybera®) programme for the correction of lipoprotein lipase deficiency. The company had previously...

BeNeLuxBelgiumNetherlandsLuxembourg

20.05.2008

Brussels – Unprocessed grains of Syngenta’s herbicide-tolerant biotech maize GA21 have been approved for use in the European Union for an initial period of 10 years, according to a European Commission decision. The genetically...

BeNeLuxBelgiumNetherlandsLuxembourg

20.05.2008

Brussels – To ensure that new genetic tests become available to patients, European human geneticists have called for a ban on patents covering disease genes and related SNPs. Additionally, the group under Prof. Gert Matthijs...

BeNeLuxBelgiumNetherlandsLuxembourg

20.05.2008

The Hague – The District Court of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin – the active ingredient of Pfizer’s bestseller Lipitor – would be infringed by a competitor product from Indian...

BeNeLuxBelgiumNetherlandsLuxembourg

20.05.2008

Maastricht – The Netherlands, Belgian and German regions will cooperate closer in the development of the life sciences after representatives signed a letter of intent at the 2nd Biomedica conference in Maastricht. Dutch ministers...

BeNeLuxBelgiumNetherlandsLuxembourg

20.05.2008

Amsterdam – The Netherlands will become the seventeenth country in Western Europe to recommend HPV vaccination for adolescent girls. The Dutch Health Council has recommended to the ministry that the vaccine be given to to...

BioPeople, BeNeLuxBelgiumNetherlandsLuxembourg

26.03.2008

UCB has appointed Fabrice Enderlin, the company’s Executive Vice President of Corporate Human Resources, as a new member of UCB’s Executive Committee. Enderlin will be taking over the position from Jean-Pierre Pradier, who will...

BeNeLuxBelgiumNetherlandsLuxembourg

19.03.2008

Mechelen – Belgian drug discovery company Galapagos NV has withdrawn its listing on London’s Alternative Investment Market AIM. Instead, the board of directors has decided to launch a “Level 1 American Depositary Receipt (ADR)”...

Displaying results 161 to 170 out of 304

< Previous 161-170 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/16/article/fluorescent-tumours-in-the-clinic.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA98.35 CHF13.70%
  • EPIGENOMICS3.37 EUR6.65%
  • FORMYCON6.85 EUR1.48%

FLOP

  • MOLOGEN7.38 EUR-5.87%
  • EVOTEC3.74 EUR-5.08%
  • CYTOS0.25 CHF-3.85%

TOP

  • SANTHERA98.35 CHF53.7%
  • BB BIOTECH141.00 EUR6.3%
  • ADDEX3.98 CHF4.2%

FLOP

  • WILEX2.25 EUR-24.7%
  • MOLOGEN7.38 EUR-18.8%
  • 4SC1.22 EUR-15.9%

TOP

  • SANTHERA98.35 CHF4121.0%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR179.3%

FLOP

  • CYTOS0.25 CHF-93.6%
  • MEDIGENE4.55 EUR-67.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 28.08.2014


Current issue

All issues

Product of the week

Products